Adding Hormone Therapy to PORT Might Not Benefit Patients with Recurrent Prostate Cancer and PSA of 0.5 ng/mL or Less By Ogkologos - March 5, 2026 247 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the POSEIDON meta-analysis of the MARCAP consortium Source RELATED ARTICLESMORE FROM AUTHOR Ovarian Reserve Better Indicator of Adjuvant Chemotherapy Benefit than Self-Reported Menopause Status, Age, or Other Hormone Levels Immune-Modulating SBRT Plus Anti-PD-L1 May Convert Immune-Cold ER-positive, HER2-negative EBC Into More Inflamed Tumours and Improve Response EMA Recommends Extension of Therapeutic Indications for Serplulimab MOST POPULAR Looking back at a life-changing clinical trial September 16, 2022 How to Find an Oncologist Who’s an LGBTQ+ Ally: An Expert... April 14, 2021 Lack of Benefit of Adding Immune Checkpoint Inhibitors to Chemotherapy in... December 6, 2021 Get the Most out of Seasonal Fruits! December 28, 2020 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for a Biosimilar Bevacizumab, Onbevzi Neoadjuvant Nivolumab Plus Ipilimumab Leads to a Pathological Response in a... New on NCI Websites for December 2018 How Does Ovarian Cancer Form? A New Study Points to MicroRNA
